Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Radiotherapy (RT) remains a cornerstone in the treatment of thoracic malignancies; however, approximately one-third of patients with non-small cell lung cancer (NSCLC) develop Grade ≥ 2 radiation-induced lung injury (RILI). Despite its clinical significance, no pharmacologic standard of care has been established for RILI. Pirfenidone, an antifibrotic agent with anti-inflammatory and antioxidant properties, has demonstrated potential in preclinical models of RILI. This study aimed to evaluate the clinical efficacy and safety of pirfenidone in NSCLC patients with RILI following thoracic RT.
Methods: We retrospectively analyzed 33 NSCLC patients diagnosed with Grade ≥ 2 RILI who received pirfenidone (400 mg three times daily) in combination with standard-of-care treatment. The corticosteroid regimen included intravenous methylprednisolone (20-40 mg/day for 5 days), tapered and discontinued by Day 14. Radiologic response was assessed via monthly high-resolution computed tomography (HRCT), and symptoms were graded using common terminology criteria for adverse event(CTCAE) version 5.0. Dose-volume metrics (V5, V20, mean lung dose) were recorded and analyzed for correlation with RILI severity.
Results: Radiographic improvement was observed in 78.8% (26/33) of patients, with a trend toward increased response over time. No Grade ≥ 3 pirfenidone-related adverse events (AEs) were observed. One patient experienced transient Grade 3 thrombocytopenia attributed to prior chemotherapy. Univariate analysis showed no significant association between baseline characteristics and treatment response. Four patients with overlapping RILI and immune-related pneumonitis also showed clinical improvement.
Conclusions: Our findings provide preliminary evidence supporting the clinical benefit and tolerability of pirfenidone for RILI in NSCLC patients. These results warrant further investigation in prospective controlled trials to establish its role in routine clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403526 | PMC |
| http://dx.doi.org/10.1186/s12885-025-14896-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database.
J Thorac Oncol
July 2025
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Introduction: TNM staging systems create prognostic categories by anatomic extent of disease. Whether therapeutically important molecular alterations in NSCLC augment the prognostic information of TNM staging is unclear. To study this, we analyzed molecular data from the ninth edition of the lung cancer staging system.
View Article and Find Full Text PDFThe International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification.
J Thorac Oncol
August 2025
Department of Radiation Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
Introduction: Cigarette smoking negatively affects lung cancer prognosis. Incorporating smoking history into stage-stratified survival analyses may improve prognostication.
Methods: Using the International Association for the Study of Lung Cancer ninth edition NSCLC database, we evaluated the association between smoking status at diagnosis and overall survival (OS) using Kaplan-Meier plots and multivariate Cox proportional hazard regression models adjusted for age, region, sex, histologic type, performance status, and TNM stage.
TMBquant: an explainable AI-powered caller advancing tumor mutation burden quantification across heterogeneous samples.
Brief Bioinform
August 2025
Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwu Road, Xincheng District, Xi'an 710004, China.
Accurate tumor mutation burden (TMB) quantification is critical for immunotherapy stratification, yet remains challenging due to variability across sequencing platforms, tumor heterogeneity, and variant calling pipelines. Here, we introduce TMBquant, an explainable AI-powered caller designed to optimize TMB estimation through dynamic feature selection, ensemble learning, and automated strategy adaptation. Built upon the H2O AutoML framework, TMBquant integrates variant features, minimizes classification errors, and enhances both accuracy and stability across diverse datasets.
View Article and Find Full Text PDFLazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.
Drug Dev Res
September 2025
R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with "epidermal growth factor receptor (EGFR)" mutations playing a pivotal role in tumor progression and carcinogenesis. "Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)," such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives.
View Article and Find Full Text PDFThe role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer.
Rep Pract Oncol Radiother
August 2025
Department of Oncology and Radiotherapy, University Hospital in Pilsen, Pilsen, Czech Republic.
In the recent years, the clinical stage where the cancer has spread beyond the primary site, but has not yet metastasised extensively, and which is known as oligometastatic disease (OMD), has become an object of interest to radiation oncologists. OMD is a kind of an "umbrella term" for a variety of clinical situations. This review focuses on the role of radiotherapy (RT) in the treatment of oligometastatic non-small cell lung cancer (OM-NSCLC).
View Article and Find Full Text PDF